Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 1;60(7):e225-e226.
doi: 10.1093/rheumatology/keaa880.

Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination

Rebecca H Haberman  1 , Rochelle Castillo  1 , Jose U Scher  1
Affiliations
Case Reports

Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination

Rebecca H Haberman et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Left upper arm psoriasis over the course of treatment (A) June 2019 prior to first ustekinumab injection. (B) January 2020 prior to the second ustekinumab injection. (C) September 2020, after two injections of ustekinumab.
See this image and copyright information in PMC

References

    1. Mease PJ, Gladman DD, Papp KA et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69:729–35. - PubMed
    1. Ritchlin C, Scher JU. Strategies to improve outcomes in psoriatic arthritis. Curr Rheumatol Rep 2019;21:72. - PubMed
    1. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81. - PubMed
    1. Mease PJ, Gladman DD, Collier DH et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 2019;71:1112–24. - PMC - PubMed
    1. Coates LC, Tillett W, D’agostino MA et al. OP0050 adalimumab introduction versus methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis: results from randomized phase 4 control study. Ann Rheum Dis 2020;79:33. - PubMed

Publication types